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Proper indicationsforsecond-looksurgery inpatients withcolorectal cancer havealwaysbeen a controversialsubject. The surgical
literature suggests beneﬁt in a reoperation, where a limited extent of cancer is discovered and then resected with negative margins.
However, patients are often subjected to a negative exploratory laparotomy or an intervention that is unable to achieve an R-0
resection; in these circumstances, little or no beneﬁt occurs. Unfortunately, an unsuccessful repeat intervention may place the
patient in a worse condition, especially if morbidity occurs. This paper seeks to identify the clinical parameters of a primary
colorectal cancer and a followup plan that are associated with cancer recurrence that can be deﬁnitively addressed by the second
look surgery. New surgical technologies, including cytoreductive surgery with peritonectomy and perioperative intraperitoneal
chemotherapy with hyperthermia, are suggested for use in this group of patients. This new management strategy used in patients
with local-regional recurrence may result in a high proportion of patients converted from a second-look positive patient to a
long-term survivor.
1.Introduction
Second-look surgery in colorectal cancer patients who
developprogression afterthesurgical removal oftheprimary
malignancy has been extensively explored in the surgical
literature [1–5]. Indications for a second intervention in
colorectal cancer patients have prompted multiple presen-
tations at international meetings and have always been
the subject of much debate. Wangensteen and colleagues
organized a planned approach to reoperative surgery in
asymptomatic gastrointestinal cancer patients and consci-
entiously critically evaluated the long-term results [6]. As
their clinical experiment evolved, a group of symptomatic
second look patients who had clinical evidence of recurrent
disease were added to the planned second look in patients
who had no signs or symptoms of progressive disease.
Minton and colleagues revisited the problem of patient
selection for second-look surgery by using an elevation of
carcinoembryonic antigen (CEA) obtained at one- to two-
month intervalspostoperativelytoselect patientsforsecond-
look surgery [7].
These paper constitute an important part of the evo-
lution of colorectal cancer surgery. Griﬃn and colleagues
(reviewing the Wangensteen eﬀort) and Minton and col-
leagues insist, in their summary statements, that symp-
tomatic and asymptomatic second-look surgery in patients
with colorectal cancer must be considered as an important
option in patient management and constitutes the major
rationale for meticulous follow-up management strategies
[6–8]. Unfortunately, when these early studies were per-
formed, the repeat surgical intervention occurred without
special treatments; their reoperative surgical technology was
limited to a more aggressive surgical extirpation of recurrent
cancer. Oftentimes, documentation of progressive disease at
the time of second-look exploration was not followed by
potentially curative surgical extirpation.
Despite much discussion and multiple publications, the
modern revisions of the indications for second-look surgery
have never been forthcoming. Wangensteen and colleagues
suggested reoperation based on lymph node positivity at
the time of primary colon or rectal resection. Minton
sought to more eﬀectively select his patients for second look2 International Journal of Surgical Oncology
by using a progressively rising CEA blood test. However,
patientsoperatedonforsymptoms(ratherthanprogressively
rising CEA blood tests) had the same beneﬁts at second-
look surgery. In both of these clinical experiments, some
patientswere found to be disease-free (negative second look)
and suﬀered from the morbidity and even an occasional
mortality associated with repeat laparotomy. Also, in too
many patients, the disease had progressed to an unresectable
state. The indications for second look did not select out
those patients most likely to beneﬁt from reoperative
surgery.
This paper seeks to identify the clinical parameters and
follow-up strategies of a primary colorectal cancer that
are associated with a pattern of treatment failure that can
be deﬁnitively addressed with a second-look surgery. We
identify the clinical features of the primary disease process
that will allow the cancer surgeon to most knowledgeably
select patients for a successful second-look surgery. Also, the
useoftumormarkersandCTinfollow-upareintegratedinto
follow-up regimens. In addition, we identify more eﬀective
treatment options for colorectal rectal cancer eradication in
the operating room at the time of reoperation. The use of
cytoreductive surgery with peritonectomy combined with
perioperative hyperthermic chemotherapy are presented as
an e wa n dm o r ee ﬀective combined management plan to
be added to the reoperative surgery. Documentation of
improved survival of a subset of patients is the goal of this
revised approach for the surgical evolution of second-look
surgery in colon and rectal cancer patients.
2.AShort HistoryofSecond-LookSurgeryfor
ColorectalCancer
In 1948, Wangensteen at the University of Minnesota
initiated a new plan for improved management of intra-
abdominal cancer [9]. He reasoned that surgery was the
only eﬀective tool by which to cure primary gastrointestinal
cancer; therefore, more radical cancer surgery could be used
to extirpate isolated sites of disease progression and thereby
improve survival. He identiﬁed lymph node-positive disease
at the time of primary cancer resection as an indication
for a systematic plan of reoperation. Every six to eight
months, surgical reexploration of the abdomen and pelvis
was performed; this reoperation at regular intervals was
scheduled until no cancer was found or until the disease
was beyond surgical control. Initially, patients were only
taken to surgery in an asymptomatic state; however, as
the clinical results from the reoperative treatment strategies
evolved,patientswithsymptoms fromrecurrent disease were
included in the series.
Table 1 summarizes the results of second-look surgery
for colon cancer after 20 years of data accumulation. In 36
patients who had a positive second-look, six patients (17%)
were “converted” from a second look positive to a disease-
free status. In 47 patients who had a symptomatic second
look, seven patients (15%) were converted by reoperative
surgery to long-term survival. In their review of these data
from the second look approach, Griﬀen and colleagues
concludedthat “signiﬁcant patient survival resulted from the
Table 1: Second-look surgery in patients with cancer of the colon
(reprinted from [6] with permission).
Second-
look
negative
Second-
look
positive
Symptomatic
look
Number of patients 62 36 47
Operative deaths 2– 3.2%
∗ 6–17% 7–15%
Recurrent cancer† 12–19% 24–67% 33–70%
Living and well, last
look negative 41 4 4
Living and well, last
look positive —0 3
Living with residual 1 0 0
Dead from other
than cancer 10 2 0
Total converted — 6–17% 7–15%
∗One patient had residual cancer and died at ﬁfth look.
†Considered failures in negative-look group.
second look approach in patients with cancer of the colon.
This eﬀort should be continued and extended” [8].
These favorabledata regarding patients “converted”from
a positive second look to long-term survival were oﬀset, at
least in part, by the impact this management plan had on
the entire group of patients. Extensive surgical procedures
to remove recurrent disease led to an operative mortality of
17% in the patients who had a positive second look. Also,
in the patients with the symptomatic second look, there was
a 15% operative mortality. In interpreting these formidable
mortality statistics, it must be pointed out that this high
operative mortality occurred in patients identiﬁed as having
progressive disease. These patients would presumably have
gone on to die of this disease in the near future. However,
their lives were cut short as a result of the operative
mortality.
Perhaps most damaging to the concept of a planned
secondlookwerethetwopatients(3.2%)whodiedpostoper-
ativelyaftera negative exploration.These patientsdying with
a negative second look may have been long-termsurvivors in
the absence of this aggressive surgical treatment strategy.
There have been eﬀorts to reﬁne the indications for
second-look surgery. In the mid-1970s, a collaborative eﬀort
of the Peter Bent Brigham Hospital and the Mallory Gas-
trointestinal Laboratory searched for clinical relationships
between the carcinoembryonic antigen (CEA) and the natu-
ral history of surgically treated colorectal cancer. Sugarbaker
and colleagues determined that serial carcinoembryonic
antigen assays determined at 3 monthly intervals after a
colonorrectalcancerresectionwoulddetectoccultrecurrent
disease approximately 6 months prior to clinical signs and
symptoms [10]. These results led to a clinical study to use
CEA as a surveillance test for recurrent colon or rectal
cancer after a potentially colon or rectal cancer resection.
Steele and colleagues reported on a prospective study of 75
patients who had CEA assays performed at approximately
2-month intervals. Fifteen of 18 tumor recurrences were
ﬁrst diagnosed by increasing CEA values despite no otherInternational Journal of Surgical Oncology 3
evidence of progressive disease. In 4 of these 15 patients,
complete resection of recurrent cancer with a potential for
cure was reported. Long-term follow-up of the total number
of patients “converted” from recurrent disease to long-term
survival was not available [11].
Attiyeh and Sterns collected data on 32 patients who
underwent second-look surgery for “a signiﬁcant CEA
elevation”following a curativeresection for adenocarcinoma
of the large bowel [12]. Not surprisingly, the total number of
patients from which these 32 with a rising CEA blood test
were selected is not given available. These 32 patients had
37 exploratory procedures with 16 of 37 (43%) potentially
curative resections. Again, the number of patients “con-
verted” from recurrent disease to long-term survival was not
available from this paper.
Perhaps the most reliable data regarding the possible
beneﬁts of second-look surgery in colorectal cancer patients
comes from the prospective evaluation of this strategy
reported in 1985 [7]. Minton and colleagues initiated a
multi-institutional study. They prospectively collected data
on 400 patients operated on at 31 diﬀerent institutions.
His paper emphasizes that the surgeons performing the
second-look procedure had advanced training in reopera-
tive surgery. These 400 patients had 43 carcinoembryonic
antigen-directed reoperations and 32 symptomatic second-
lookreoperations. At5years following the secondlook, 22of
75 patients (29%) remained disease-free at 5 years. Minton
and colleagues, as a result of their study, recommended
meticulous surveillance of Dukes stage C2 cancer following
primary colorectal cancer resection, CEA determinations at
1- to 2-month intervals postoperatively, and reoperation
before the serial CEA test exceeded 11ng/ml.
As a result of this and other eﬀorts to use postoperative
monitoring of CEA in patients at high risk for recurrence of
colon and rectal cancer, a standard of practice has evolved
in patients surgically treated for colorectal cancer. If a
progressive rise in theCEA bloodtest occurs, patientsshould
be considered for reoperation. Radiologic tests should be
performed to show that the elevated CEA determination
occurs in the absence of systemic disease or unresectable
disease in the abdomen or pelvis. Minton and colleagues
should be credited with establishing a strong rationale
for meticulous follow-up of colorectal cancer patients
and a reasonable likelihood of beneﬁt from second-look
surgery.
Goldberg and coworkers pooled data in a prospective
follow-up of 1247 patients with resected stage 2 or stage 3
colon cancer [13]. 548 patients had recurrence of colon can-
cer, and second-look surgery was attempted in 222 patients
(41%). In 109 patients (20%), potentially curative surgery
resulted. In patients who came to curative intent second-
look surgery, recurrent disease was identiﬁed by radiologic
follow-up in 36 patients, serial CEA tests in 41 patients, and
symptoms in 27 patients. The 5-year disease-free survival
of these 109 patients was 23%. The surgical mortality was
2%. These authors concluded that postoperative follow-up
testing of patients with colon cancer may identify recurrent
disease in some and that the second-look surgery can result
in a long-term disease-free survival.
3.Pathobiologyof ColorectalCancer
RecurrenceafterSurgicalResection
There can be no doubt that the second-look approach
initiated by Wangensteen established a new paradigm for a
reoperative approach to patientswith colorectal cancer. Also,
the data on sites of recurrence carefully collected by this
grouphashadaprofoundeﬀectuponthesurgicaltechnology
used for primary colorectal cancer resection. Gunderson
and Sosin reported the anatomic sites of surgical treatment
failure that were identiﬁed at the time of reoperation in 74
patients [14]. They report that distant metastases alone was
uncommon (8%) but occurred as a component of treatment
failure in 50% of the group. Local failure or regional lymph
node metastases occurred in 48% of patients as the only site
of surgical treatment failure. In 92%, local failure occurred
by itself or occurred in combination with distant metastases.
Gunderson’s data established that local-regional surgical
treatment failure was a signiﬁcant part of the natural history
of colorectal cancer.
Inahistoricallyimportant paperthathadaninﬂuenceon
surgical technology for colorectal cancer resection, Lofgren
et al. examined the pattern of surgical treatment failure in
a special group of 47 patients. These patients had a local-
regional recurrent disease but were lymph node negative
within the primary cancer specimen [15]. From these obser-
vations, Lofgren and coworkers reasoned that a mechanism
of treatment failure other than lymph node metastases must
have caused recurrent disease in these patients. Forty-one
of these 47 recurrences were within the operative ﬁeld and
adjacent to or involved the suture line. They reasoned, and
this was a novel explanation in 1957, that cancer cells from
the primary tumor were left behind and disseminated by the
surgeon at the time of removal of the primary lesion. Prior
to this publication, colorectal cancer recurrence was thought
to be limited tohematogenousand lymphaticdissemination.
These new concepts regarding surgical treatment failure led
to the promotion of no-touch isolation technique and the
total mesorectal excision [16, 17].
As shown in Figure 1, colorectal cancer recurrence
can be attributed to hematogenous dissemination, usually
to the liver, intracoelomic dissemination at the resection
site as local recurrence, or within the peritoneal cavity as
carcinomatosis. Progression of lymph nodal disease causing
para-aortic lymph node metastases is an unusual pattern
of dissemination. As indicated by the ring diagram, these
mechanisms of treatment failure can occur in isolation or in
combination [18]. There can be no doubt that as a result of
data accumulated at the time of second-look surgery, local
recurrence and peritoneal seeding are important anatomic
sites of disease progression of surgically treated colon and
rectal cancer.
Sugarbaker and coworkers suggested that peritoneal
carcinomatosis and local failure are caused by the same
mechanism [19]. Surgical trauma causing dissemination of
cancer cells from the primary malignancy is an unfortunate
but common occurrence with the cancer resection. Free
intracoelomic cancer cells can result from surgical trauma to
the primary tumor, blood, or lymph contaminated by cancer4 International Journal of Surgical Oncology
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Figure 1: Ring diagram shows that hematogenous metastases and
cancer seeding can occur in isolation or in combination with
other sites of surgical treatment failure. High-density seeding at the
resection site causes a layering of cancer; low-density seeding at a
distance results in peritoneal carcinomatosis (reprinted from [18]
with permission).
cells being spilled into the resection site or free peritoneal
cavity or from cancer cells disseminated prior to or at the
time of cancer resection from full thickness invasion of
the bowel wall. These spilled cancer cells can accumulate
at the resection site usually in high density and result in
local recurrence. They can accumulate at lower density
at distant sites within the peritoneal cavity as peritoneal
carcinomatosis. For example, in a rectal cancer, the hollow
of the sacrum would be favored by gravity for accumulation
of the largest number of cancer cells. Consequently, if the
primary rectal cancer is traumatized, a large proportion of
patients will suﬀer a local recurrence. The conﬁnes of the
pelvis make full exposure diﬃcult so that surgical trauma
to the primary cancer is a great danger. The traumatized
primary cancer may only lose a few cells, but they would be
expected to stick, implant, and then vascularize within the
adjacent tissues. By this theory, the resection site of a cancer
is at great risk for progressive disease.
However, not all the cancer cells disseminated from
the primary malignancy must implant locally. Some may
gain access to the free peritoneal cavity. Cancer cells within
intraperitoneal blood clot will later be organized as recur-
rences within abdominal adhesions. Free cancer cells will
move along with peritoneal ﬂuid to distant sites such as the
pelvis, beneath the right hemidiaphragm, or in the right and
left paracolic sulcus. With small amounts of intraperitoneal
ﬂuid, peritoneal seeding proximal to the resection site is
expected. With larger amounts of ascites ﬂuid or with
mucinous cancer cells, distant spread of carcinomatosis will
occur.
Cancer cells may enter the portal venous system and
cause liver metastases. However, cancer cells present within
venous blood spilled at the time of primary cancer resection
may ﬁnd their way into the free peritoneal cavity. These
free cancer cells may cause resection site recurrence or
carcinomatosis.
4.New TreatmentOptionsAvailable for
Second-LookSurgery
Second-looksurgery has a muchgreaterlikelihood ofsuccess
now than in the past. The knowledgeable use of systemic
chemotherapy has reduced the proportion of patients who
succumb to progression of systemic micrometastatic disease.
The surgical technology for liver resection of colorectal
metastases has evolved over the last two decades; liver
secondaries are resected if the patient can be made clinically
disease-free by liver surgery with minimal morbidity and
almost no mortality [20]. Also, surgical technologies for
managing local recurrence and peritoneal seeding within
the abdomen and pelvis have become available. Visceral
resections, peritonectomy procedures, and hyperthermic
intraperitoneal chemotherapy oﬀer a treatment option that
may be successful in as many as 50% of patients with
carcinomatosis [21]. There can be no doubt that the more
limited the extent of carcinomatosis, the larger the beneﬁt
from deﬁnitive treatment.
Extended lymph node dissections so that all possible
sites for lymphatic dissemination from colon or rectal cancer
are now advocated [22]. Although segmental resections of
a colon cancer may have been popular a decade ago, new
data strongly supports the surgical removal of all regional
lymph nodes that drain the primary cancer. Countless
lymphatic channels must be transected in a colon or rectal
cancer resection. Cancer cells in lymphatic channels may
be lost into the abdominal or pelvic space. A logical
conclusion from this hypothesis is that local recurrence is
more frequent in patients with colorectal cancers and lymph
node metastases [23]. In primary colorectal cancer resection
and in reoperative surgery, wide dissection of the colorectal
mesentery to the superior mesenteric artery and vein on the
right or aorta on the left is indicated.
5.New IndicationsforSecond-LookSurgery
The new concept in colorectal cancer resection demands
complete clearance of the primary malignancy and total
containment of the malignant process during the colon
or rectal cancer resection [24]. Unfortunately, there are
groups of patientswho will fail eventhe most knowledgeable
and skillful eﬀorts to deal deﬁnitively with the primary
cancer. Also, some patients (approximately 20%) will show
peritoneal dissemination of the primary cancer at the time
of initial diagnosis [25]. The patients who are at high risk
for implantation of cancer seedlings either as local-regional
recurrence or peritoneal carcinomatosis can be identiﬁed
through a careful evaluation of the clinical presentation ofInternational Journal of Surgical Oncology 5
Table 2: Patients with primary colorectal cancer identiﬁed to
be at high risk for local-regional recurrence and/or peritoneal
carcinomatosis.
(1)Visible evidence of peritoneal carcinomatosis.
(2) Ovarian cysts showing adenocarcinoma suggested to be of
gastrointestinal origin.
(3) Positive cytology either before or after cancer resection.
(4) Adjacent organ involvement or cancer-induced ﬁstula.
(5) Obstructed cancer.
(6) Perforated cancer.
(7) T3 mucinous cancer.
(8) T4 cancer or a positive “touch prep” of the primary cancer.
(9) Cancer mass ruptured with the resection.
(10) Positive lateral margins of excision.
the primary cancer and a study of the pathology report. Of
course, patients who present with peritoneal dissemination
at the time of primary cancer resection will consistently
show progression of carcinomatosis. The high-risk patients
include mucinous T3 and all T4 cancers, cancers with
adjacent organ involvement, cancers with limited peritoneal
seeding, cancers with ovarian involvement, cancers with
positive peritoneal cytology, and cancers that are ruptured
intraoperatively. Also, patients who have a perforation
through the primary tumor are known to have a high
incidence of local and regional cancer recurrence [25].
Table 2 lists the patients at high risk for progression of local-
regional disease or peritoneal carcinomatosis. These patients
canbeidentiﬁedaseligibleforaplannedsecondlooksurgery
from their clinical presentation and from their pathology
reports in the absence of evidence of recurrent cancer.
One requirement of colorectal cancer surgery currently
not standard of practice should be added to primary cancer
resection in order to thoroughly evaluate patients for this
revised second-look approach. A cytology of the peritoneal
surface of the primary tumor (optimally a “touch prep”)
should occur prior to a colorectal cancer resection. Also,
aspiration of ﬂuid for a cytological study of the space
beneath the right lobe of the liver and of the pelvis should
occur. Finally, a cytological study of the whole abdomen
following the completion of the colorectal cancer resection
is important. Patients with cytologically positive colon or
rectal cancer are at high risk for death from progressive
disease [26]. These patients with a positive “touch prep” or
positive cytology are identiﬁed as high risk for local-regional
recurrence and eligible for second-look surgery.
6.Implementationofa New Second-Look
TreatmentStrategy
With a group of colorectal cancer patients identiﬁed who are
at high risk for local-regional recurrence and with a new and
more eﬀective liver resection and peritoneal surface treat-
ment strategies available, a consistent application of second-
look surgery should be clinically tested. This comprehensive
treatment plan would include three groups of patients:
Table 3: Ineligibility requirements in patients considered for
second-look surgery.
Major:
Liver metastases >4
Performance status >2
Serious medical condition
Renal failure with creatinine >3
Cardiac failure with ejection fraction <50%
Malnutrition
Radiologic study showing systemic disease
Minor:
Obesity
Low rectal cancer
Intestinal obstruction from progressive cancer or a long interval
between cancer recurrence and second look
(1)patients at high risk for recurrence by surgical and patho-
logic ﬁndings, (2) patients in the follow-up with symptoms
orsignsthatsuggestdiseaseprogression,and(3)patientsthat
show a progressive rise in CEA. However, in order to keep
the morbidity and mortality with this reoperative surgery
at a minimum, ineligibility requirements for this group of
patients should be enumerated. Table 3 lists those patients
who are not considered reasonable candidates for the revised
second-look strategy. Patients with more than four liver
metastases or liver metastases that cannot be resected are
ineligible. Of course, patients who have a poor performance
status or serious medical conditions and are not likely to
survive the second-look surgery should not be included.
Patients who have had a low rectal cancer with recurrence
attheresection site arenotgoodcandidatesforcytoreductive
surgeryandhyperthermicintraperitoneal chemotherapyand
are poor candidates for reoperation [27]. Of course, patients
who have unresectable systemic disease (especially disease in
the bone marrow or numerous pulmonary metastases) are
not candidates for second-look surgery. The most modern
radiologic technologies for detecting systemic disease should
be used prior to a reoperative event. This would include CT
scan of the chest, abdomen, and pelvis and PET scan.
The ﬁnal ineligibility requirement listed in Table 3
concerns the interval between primary cancer resection and
the second look. In patients at high risk for local-regional
recurrence, the intervention should occur within 1 year of
the primary cancer resection. This time limitation is an
attempt for this clinical pathway to identify patients with
disease recurrence that has a limited progression within
the abdomen and pelvis. For those patients with peritoneal
carcinomatosis, it seeks to identify patients with a peritoneal
cancerindex oflessthan10.There isnodoubtthatoneofthe
most important requirements for success with cytoreductive
surgery and hyperthermic intraperitoneal chemotherapy is a
low peritoneal cancer index [28].
There is some data regarding a timely second-look
surgery in colorectal cancer patients at high risk for local-
regional recurrence [29]. Elias and colleagues reported on
29 patients who had no radiologic evidence of recurrence6 International Journal of Surgical Oncology
Resected colorectal cancer
High risk for local-regional
recurrence
Clinical follow up by
symptoms and signs, CEA
and CT
Rising CEA Symptoms or
signs
Planned second look second look
Symptomatic
second look
Reoperative surgery
Positive unresectable Positive resectable Negative
Palliative surgery,
chemotherapy
Omentectomy,
HIPEC
CRS and HIPEC
CEA-directed
second-line systemic oophorectomy, and
Figure 2:Algorithmfora planned secondlook inpatients athigh riskfor local-regionalcancer recurrence. CEA: carcinoembryonicantigen;
CRS: cytoreductive surgery; HIPEC: hyperthermic intraperitoneal chemotherapy.
of colon cancer who were taken back to the operating
room because of the gross and microscopic ﬁndings at the
time of primary colorectal cancer resection. The planned
second look was within one year of the primary resection.
In 55% of patients, persistent adenocarcinoma was doc-
umented. In patients with documented disease at second
look 9 of 16 patients were disease-free at 27 months
median follow-up. These are encouraging preliminary
data.
7.AlgorithmforRevisedSecond-LookSurgery
Prior to the second-look surgery, the patients would have
radiologic tests to rule out systemic disease. CT scan of
chest, abdomen, and pelvis is suggested. Also, a PET scan is
necessary. Acolonoscopytoexaminetheentirecolonlooking
for second primary tumors and suture line recurrence is a
requirement.
Figure 2 presents an algorithm for second-look surgery
in three groups of patients. There are those patients who
have limited carcinomatosis identiﬁed at the time of primary
colon or rectal cancer resection; also, those patients who,
by a study of their clinical symptoms and signs and a
review of their pathology report, indicate that they are
at high risk for local and regional recurrence [30]. In
this group, the maximum time interval between primary
colorectal cancer resection and the planned second look
should be one year for this plan. Of course, patients with
a progressive rise in CEA or symptomatic or radiologic
evidence of disease progression will be considered for a
second-look surgery. Note in Figure 2 that patients with
a negative second look will not have a simple “open and
close” laparotomy. These patients are considered at high risk
for recurrent disease. In an attempt to protect them from
local-regional progression after their full reexploration, they
will have a greater and lesser omentectomy, oophorectomy,
andahyperthermicintraperitonealchemotherapyprocedure
(HIPEC).Itispossible thata limitedsurgery plusHIPECwill
improve the outlook in patients with a negative second look
and add little to the expected low morbidity and mortality.
In patients who have a positive second look, there
will be cytoreductive surgery which would involve the
necessary peritonectomy procedures and visceral resections
[31]. Following surgery to remove all visible evidence of
disease, hyperthermic intraperitoneal chemotherapy would
be performed [32].International Journal of Surgical Oncology 7
Table 4: Endpoints of revised guidelines for second-look surgery.
Credits Debits
(1) Percentage of patients
“converted” from disease
recurrence to ﬁve-year
survival.
(1) Percentage of patients with
a negative second look.
(2) Median time to recurrence
and median survival of
patients with a positive second
look who are resected.
(2) Morbidity and mortality
of patients with a negative
second look.
(3) Median time to recurrence
and median survival of
patients with a positive second
look who are unresectable.
(3) Morbidity and mortality
of patients with a positive
second look.
(4) Cost of reoperative
surgery.
(5) Cost of followup program.
8.Evaluationof theRevisedSecond Look
The evaluation of this clinical project must be prospective
and thorough. The primary endpoint for the study, which
will require approximatelya 10-yearfollow-up, isthe percent
of patients converted from a positive second look to long-
termsurvival.Asecondaryendpointwouldbethepercentage
of patients who have a positive second look as compared to
those who have a negative second look. A third endpoint is a
comprehensive morbidity and mortality assessment of both
positive and negative second-look procedures. At the end
of data accumulation, a summary of the credits and debits
of this approach using the revised second-look surgery will
become available (Table 4).
9.Timing ofReoperativeSurgery,
ProactiveorPalliative
A large proportion of health care costs occur within the
last 6 months of life. For gastrointestinal cancer, recurrence
within the abdomen and pelvis allowed to progress to
intestinal obstruction, ﬁstula, or abscess brings about a
clinical situation which requires extensive and expensive
healthcare. Clear guidelines for reoperative colorectal cancer
surgery to prevent this devastating clinical situation are
not available. Can a reoperative surgical procedure add a
reasonable length of good-quality life? Which patients will
proﬁtfrom asurgicalinterventionandwhich patientsshould
be told that further surgery is not an option? If a second-or
third-look surgical intervention is beneﬁcial when should it
be performed? Early, before symptoms occur, or later after
patients have lost gastrointestinal function? If the revised
guidelinessuggestedinthispaperforsecond-looksurgeryare
placed into practice, can we prevent local-regional failure in
a signiﬁcant proportion of patients and thereby signiﬁcantly
reduce health care costs? This group of patients at high risk
for loss of local control may beneﬁt in terms of quality of life
and improved survival by proactive early intervention rather
than palliative surgery after symptoms of local-regional
disease has occurred.
10.Conclusions
A new management plan for patients at high risk for
intraabdominal colorectal cancer recurrence is suggested.
There are three criteria by which to select patients for a
second look: (1) a high risk of local-regional recurrence
of cancer, (2) a rising CEA blood test, or (3) symptoms
and signs of disease recurrence. Accumulated data shows
that early intervention results in a high likelihood of
being converted from a second-look positive group to a
long-term survivor. New cytoreductive surgical techniques
including peritonectomy and HIPEC will be used eradicate
abdominal and pelvic recurrence. Also, improved techniques
for management of limited liver metastases in combination
with peritoneal carcinomatosis are appropriate. From this
literature review, the credits and debits for a revised second-
look approach to colorectal cancer were formulated. The
major credit will be the proportion of patients converted
from a positive second look to a long-term survivor. The
debits will be morbidity and mortality of the second look
for all patients and the cost of the interventions. Important
will be morbidity and mortality of those patients who have a
negativesecondlook.Aprojectedincidenceofpositiveversus
negative second look is 50%. A projected survival of patients
with a positive second look converted to a disease-free status
is 50% at ﬁve years.
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